Home/Filings/4/0001628280-24-024943
4//SEC Filing

Brakewood Harold Eugene 4

Accession 0001628280-24-024943

CIK 0001790340other

Filed

May 22, 8:00 PM ET

Accepted

May 23, 4:15 PM ET

Size

12.8 KB

Accession

0001628280-24-024943

Insider Transaction Report

Form 4
Period: 2024-05-21
Brakewood Harold Eugene
Chief Business Officer
Transactions
  • Award

    Stock Option

    2024-05-21+165,000165,000 total
    Exercise: $3.01Exp: 2033-03-31Class A Common Stock (165,000 underlying)
  • Disposition to Issuer

    Stock Option

    2024-05-21165,0000 total
    Exercise: $9.71Exp: 2033-03-31Class A Common Stock (165,000 underlying)
  • Disposition to Issuer

    Stock Option

    2024-05-2160,5000 total
    Exercise: $6.09Exp: 2034-02-08Class A Common Stock (60,500 underlying)
  • Award

    Stock Option

    2024-05-21+60,50060,500 total
    Exercise: $3.01Exp: 2034-02-08Class A Common Stock (60,500 underlying)
Footnotes (3)
  • [F1]On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
  • [F2]The option vests and becomes exercisable as to 25% of the underlying shares on January 23, 2024 and then in equal monthly installments over the subsequent three years, subject to Mr. Brakewood's continued employment through each applicable vesting date.
  • [F3]The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028.

Issuer

Immuneering Corp

CIK 0001790340

Entity typeother

Related Parties

1
  • filerCIK 0001969578

Filing Metadata

Form type
4
Filed
May 22, 8:00 PM ET
Accepted
May 23, 4:15 PM ET
Size
12.8 KB